Systematic antibody and antigen-based proteomic profiling with microarrays

Science for Life Laboratory, Department of Proteomics, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden.
Expert Review of Molecular Diagnostics (Impact Factor: 3.52). 03/2011; 11(2):219-34. DOI: 10.1586/erm.10.110
Source: PubMed


Current approaches within affinity-based proteomics are driven both by the accessibility and availability of antigens and capture reagents, and by suitable multiplexed technologies onto which these are implemented. By combining planar microarrays and other multiparallel systems with sets of reagents, possibilities to discover new and unpredicted protein-disease associations, either via directed hypothesis-driven or via undirected hypothesis-generating target selection, can be created. In the following stages, the discoveries made during these screening phases have to be verified for potential clinical relevance based on both technical and biological aspects. The use of affinity tools throughout discovery and verification has the potential to streamline the introduction of new markers, as transition into clinically required assay formats appears straightforward. In this article, we summarize some of the current building blocks within array- and affinity-based proteomic profiling with a focus on body fluids, by giving a perspective on how current and upcoming developments in this bioscience could enable a path of pursuit for biomarker discovery.


Available from: Burcu Ayoglu
  • Source
    • "For this type of analysis several technologies are available to allow high-throughput analysis of prostate cancer samples . This includes affinity-based proteomics with a growing number of available binding molecules toward human proteins [2], and combined with microarray assays, multi-parallel immunoassays of many samples can be achieved [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: There is a need for a better differentiation of aggressive tumors in prostate cancer to design a tailored treatment for each patient, preferably by a minimally invasive analysis of blood samples. In a previous study, we discovered a decrease of plasma levels of carnosine dipeptidase 1 (CNDP1) in association with aggressive prostate cancer. Now this relation has been investigated and characterized further by generating several new antibodies for extended analysis of CNDP1 in plasma. Multi-antibody sandwich assays were developed and applied to 1214 samples from two Swedish cohorts that confirmed decreased levels of CNDP1 in plasma from patients with advanced disease. Therein, data from CNDP1 assays allowed a better differentiation between tumor N stages than clinical tPSA, but did not when classifying T or M stages. Further investigations can now elucidate mechanisms behind decreasing levels of CNDP1 in plasma and primary in regards to lymph node metastasis.
    Translational Proteomics 12/2013; 2(1). DOI:10.1016/j.trprot.2013.12.001
  • Source
    • "In the HPA, bioinformatically designed protein fragments are employed as immunogens, as well as ligands in the subsequent affinity purification and quality control/validation of the generated antibody reagents. Together with the obvious benefit of providing reagents for determining presence or levels of virtually any expressed human protein in tissues or body fluids, there is ongoing work exploring the potential of using the protein immunogens as affinity binders for detection of disease-specific antibody populations [10]. Thus, investigating alternative microarray assay formats employing protein immunogens as affinity binders could result in improved strategies for quality control of raised antibodies as well as in novel methods for diagnostic antigen microarray tests. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Protein microarrays are useful tools for highly multiplexed determination of presence or levels of clinically relevant biomarkers in human tissues and biofluids. However, such tools have thus far been restricted to laboratory environments. Here, we present a novel 384-plexed easy to use lateral flow protein microarray device capable of sensitive (<30 ng/mL) determination of antigen-specific antibodies in ten minutes of total assay time. Results were developed with gold nanobeads and could be recorded by a cell-phone camera or table top scanner. Excellent accuracy with an area under curve (AUC of 98% was achieved in comparison with an established glass microarray assay for 26 antigen-specific antibodies. We propose that the presented framework could find use in convenient and cost-efficient quality control of antibody production, as well as in providing a platform for multiplexed affinity-based assays in low-resource or mobile settings.
    International Journal of Molecular Sciences 12/2011; 12(11):7748-59. DOI:10.3390/ijms12117748 · 2.86 Impact Factor

  • Critical care medicine 07/2011; 39(7):1823-4. DOI:10.1097/CCM.0b013e31821caf44 · 6.31 Impact Factor
Show more